Education
About Us
Working with TipRanks
Follow Us
Protagenic Therapeutics (PTIX)
NASDAQ:PTIX
PTIX Stock Chart & Stats
$1.24
-$0.02(-2.65%)
At close: 4:00 PM EST
$1.24
-$0.02(-2.65%)
Day’s Range― - ―
52-Week Range$1.46 - $14.28
Previous CloseN/A
Volume99.44K
Average Volume (3M)102.28K
Market Cap
$2.38M
Enterprise Value$5.34M
Total Cash (Recent Filing)$2.72M
Total Debt (Recent Filing)$3.16M
Price to Earnings (P/E)―
Beta-2.02
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.83
Shares Outstanding1,927,898
10 Day Avg. Volume80,054
30 Day Avg. Volume102,276
Financial Highlights & Ratios
PEG Ratio3.50
Price to Book (P/B)33.18
Price to Sales (P/S)0.00
P/FCF Ratio-7.97
Enterprise Value/Market Cap2.24
Enterprise Value/Revenue-106.15
Enterprise Value/Gross Profit-35.38
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Protagenic Therapeutics News
PTIX FAQ
What was Protagenic Therapeutics’s price range in the past 12 months?
Protagenic Therapeutics lowest stock price was $1.46 and its highest was $14.28 in the past 12 months.
What is Protagenic Therapeutics’s market cap?
Protagenic Therapeutics’s market cap is $2.38M.
When is Protagenic Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Protagenic Therapeutics’s earnings last quarter?
Protagenic Therapeutics released its earnings results on Nov 16, 2021. The company reported -$2.8 earnings per share for the quarter, beating the consensus estimate of -$4.48 by $1.68.
Is Protagenic Therapeutics overvalued?
According to Wall Street analysts Protagenic Therapeutics’s price is currently Overvalued.
Does Protagenic Therapeutics pay dividends?
Protagenic Therapeutics does not currently pay dividends.
What is Protagenic Therapeutics’s EPS estimate?
Protagenic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Protagenic Therapeutics have?
Protagenic Therapeutics has 1,927,898 shares outstanding.
What happened to Protagenic Therapeutics’s price movement after its last earnings report?
Protagenic Therapeutics reported an EPS of -$2.8 in its last earnings report, beating expectations of -$4.48. Following the earnings report the stock price went down -2.874%.
Which hedge fund is a major shareholder of Protagenic Therapeutics?
Currently, no hedge funds are holding shares in PTIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Protagenic Therapeutics
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Technical Analysis
Ownership Overview
―
Insiders
0.39% Mutual Funds
3.36% Other Institutional Investors
96.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---